title: Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
abstract: We examined the postprandial glucose regulators nateglinide and GLP-1, separately and in combination, in people with type 2 diabetes. Nateglinide inhibited DPP-4 activity, reduced GLP-1 degradation and enhanced its insulinotropic and blood glucose lowering effect. Combining nateglinide and GLP-1 derivatives may effectively control postprandial glycaemia.
authors.affiliation: Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK. patrick.bell@belfasttrust.hscni.net
authors.forename: P M
authors.initials: PM
authors.lastname: Bell
authors.forename: J
authors.initials: J
authors.lastname: Cuthbertson
authors.forename: S
authors.initials: S
authors.lastname: Patterson
authors.forename: F P M
authors.initials: FP
authors.lastname: O'Harte
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D018592:Cross-Over Studies; D003510:Cyclohexanes / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents; D008297:Male; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D019518:Postprandial Period; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine; D052216:Glucagon-Like Peptide 1